Everyone has had to wait to see a physician--either for an appointment or in a waiting room where minutes seems like hours and months can feel like years.
Imagine the havoc when an additional 30 to 46 million patients who may now have health coverage are in need of doctors. Add in an aging population and public health emergencies such as pandemics, natural disasters and bioterrorism, and the scenario becomes more catastrophic.
Subscribe
About HealthScope
HealthScope is a forum to diagnose, digest and discuss the issues facing health today.
Follow us on Twitter @apcoworldwide
Categories
Recent Authors
APCOForum.com
APCOForum.com is the home blog of APCO Worldwide. Contributors include APCO's consultants around the world.
Shared Purpose
Visit Shared Purpose, our blog on what's next for business and society.
History & Categories
Click to unfold.Recent Posts
- From Ninth Graders to Health Care Elites: A Communications Lesson on the Power of Engagement
- What’s Next in Health Care Part II: Price Transparency – is it the Holy Grail?
- Accountable Health Care: The Silent Health Care Reform
- The FDA Likes Facebook? The AMARC Hysteria
- The Need for a Medical Surge
- Health Care: Now What
- The Real Hospital Quality Measures
- Happy Healthy Weight Week?
- Personalized Medicine – from Complexity to Clarity
- APCO Forum: What’s Next in Food
Archives by Month
- May 2013 (1)
- April 2013 (2)
- March 2013 (1)
- February 2013 (3)
- January 2013 (1)
- November 2012 (1)
- October 2012 (4)
- September 2012 (3)
- August 2012 (5)
- July 2012 (2)
Blogroll
Exciting news arrived for China’s health care system with the recent release of the “Healthy China 2020” report. The report, which took 400 experts over three years to develop, was led by China’s Ministry of Health (MOH) and provides a roadmap for China to overcome some of the key health challenges facing the country. Goals to be achieved by 2020 include, for example, establishing a system that ensures basic health care for all; improving key health indicators such as life expectancy (increase to 77 years); and curbing factors that lead to chronic diseases.

Today’s biopharmaceutical companies arguably face more research and development (R&D) challenges than ever before. Despite an industry-wide surge in the past decade that has nearly doubled investments in R&D, the FDA has approved considerably fewer new drugs. Add in brand names going off patent, increased competition with generics, upsets in late-phase clinical trials and dwindling pipelines, and biopharmaceutical companies are in a rough place, often finding that they don’t have enough revenue to sustain levels of R&D. It’s no wonder why in the last five years we have been witness to several large biopharmaceutical companies buying out the entrepreneurial talent of smaller biopharmaceutical companies with more promising pipelines. At the same time, public trust and confidence in the industry (as evidenced by ample research on the topic) has steadily been declining.
From Ninth Graders to Health Care Elites: A Communications Lesson on the Power of Engagement
Catogories Health Policy | Tagged audiences, communication, engagement, nemotodes, talks, teaching, TEDMED | Leave a comment